Stroke - Pipeline Review, H2 2014

Date: October 30, 2014
Pages: 275
Price:
US$ 2,000.00 US$ 1,800.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S6B11FFE7A9EN
Leaflet:

Download PDF Leaflet

Stroke - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Stroke - Pipeline Review, H2 2014’, provides an overview of the Stroke’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Stroke Overview
Therapeutics Development
Stroke - Therapeutics under Development by Companies
Stroke - Therapeutics under Investigation by Universities/Institutes
Stroke - Pipeline Products Glance
Stroke - Products under Development by Companies
Stroke - Products under Investigation by Universities/Institutes
Stroke - Companies Involved in Therapeutics Development
Stroke - Therapeutics Assessment
Drug Profiles
Stroke - Recent Pipeline Updates
Stroke - Dormant Projects
Stroke - Discontinued Products
Stroke - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Stroke, H2 2014
Number of Products under Development for Stroke - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Development by Companies, H2 2014 (Contd..2)
Number of Products under Development by Companies, H2 2014 (Contd..3)
Number of Products under Development by Companies, H2 2014 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Comparative Analysis by Unknown Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Development by Companies, H2 2014 (Contd..2)
Products under Development by Companies, H2 2014 (Contd..3)
Products under Development by Companies, H2 2014 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2014
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1)
Stroke - Pipeline by Acorda Therapeutics, Inc., H2 2014
Stroke - Pipeline by advanceCor GmbH, H2 2014
Stroke - Pipeline by Affibody AB, H2 2014
Stroke - Pipeline by AGY Therapeutics, Inc., H2 2014
Stroke - Pipeline by Anavex Life Sciences Corp., H2 2014
Stroke - Pipeline by APT Therapeutics, Inc., H2 2014
Stroke - Pipeline by ArmaGen Technologies, Inc., H2 2014
Stroke - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014
Stroke - Pipeline by Cellular Biomedicine Group, Inc., H2 2014
Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2014
Stroke - Pipeline by CoDa Therapeutics, Inc., H2 2014
Stroke - Pipeline by D-Pharm Ltd., H2 2014
Stroke - Pipeline by Diakron Pharmaceuticals, Inc., H2 2014
Stroke - Pipeline by Dong Wha Pharma Co., Ltd., H2 2014
Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014
Stroke - Pipeline by Fina Biotech, H2 2014
Stroke - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2014
Stroke - Pipeline by GliaMed, Inc., H2 2014
Stroke - Pipeline by Green Cross Corporation, H2 2014
Stroke - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014
Stroke - Pipeline by International Stem Cell Corporation, H2 2014
Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2014
Stroke - Pipeline by Kolon Life Science, Inc., H2 2014
Stroke - Pipeline by Lacer, S.A., H2 2014
Stroke - Pipeline by LegoChem Biosciences, Inc, H2 2014
Stroke - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014
Stroke - Pipeline by Living Cell Technologies Limited, H2 2014
Stroke - Pipeline by Mapreg S.A.S., H2 2014
Stroke - Pipeline by Mast Therapeutics, Inc., H2 2014
Stroke - Pipeline by Medestea Research & Production S.p.A., H2 2014
Stroke - Pipeline by Mesoblast Limited, H2 2014
Stroke - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014
Stroke - Pipeline by Neuralstem, Inc., H2 2014
Stroke - Pipeline by Neuren Pharmaceuticals Limited, H2 2014
Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H2 2014
Stroke - Pipeline by Novavax, Inc., H2 2014
Stroke - Pipeline by Omeros Corporation, H2 2014
Stroke - Pipeline by Pharmicell Co., Ltd., H2 2014
Stroke - Pipeline by Phoenix Biotechnology, Inc., H2 2014
Stroke - Pipeline by Phylogica Limited, H2 2014
Stroke - Pipeline by PhytoHealth Corporation, H2 2014
Stroke - Pipeline by Pozen, Inc., H2 2014
Stroke - Pipeline by Q Therapeutics, Inc., H2 2014
Stroke - Pipeline by ReCyte Therapeutics, Inc., H2 2014
Stroke - Pipeline by Regado Biosciences, Inc., H2 2014
Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014
Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2014
Stroke - Pipeline by StemCells, Inc., H2 2014
Stroke - Pipeline by SynZyme Technologies, LLC, H2 2014
Stroke - Pipeline by Targazyme, Inc., H2 2014
Stroke - Pipeline by Vicore Pharma AB, H2 2014
Stroke - Pipeline by Virogenomics, Inc., H2 2014
Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014
Stroke - Pipeline by Xigen SA, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Stroke Therapeutics - Recent Pipeline Updates, H2 2014
Stroke - Dormant Projects, H2 2014
Stroke - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Stroke, H2 2014
Number of Products under Development for Stroke - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

Acorda Therapeutics, Inc.
advanceCor GmbH
Affibody AB
AGY Therapeutics, Inc.
Anavex Life Sciences Corp.
APT Therapeutics, Inc.
ArmaGen Technologies, Inc.
Cardax Pharmaceuticals, Inc.
Cellular Biomedicine Group, Inc.
CHA Bio & Diostech Co., Ltd.
CoDa Therapeutics, Inc.
D-Pharm Ltd.
Diakron Pharmaceuticals, Inc.
Dong Wha Pharma Co., Ltd.
F. Hoffmann-La Roche Ltd.
Fina Biotech
Generon (Shanghai) Corporation Ltd.
GliaMed, Inc.
Green Cross Corporation
Inbiopro Solutions Pvt. Ltd.
International Stem Cell Corporation
Jeil Pharmaceutical Co., Ltd.
Kolon Life Science, Inc.
Lacer, S.A.
LegoChem Biosciences, Inc
Ligand Pharmaceuticals, Inc.
Living Cell Technologies Limited
Mapreg S.A.S.
Mast Therapeutics, Inc.
Medestea Research & Production S.p.A.
Mesoblast Limited
Mnemosyne Pharmaceuticals, Inc.
Neuralstem, Inc.
Neuren Pharmaceuticals Limited
New Haven Pharmaceuticals, Inc.
Novavax, Inc.
Omeros Corporation
Pharmicell Co., Ltd.
Phoenix Biotechnology, Inc.
Phylogica Limited
PhytoHealth Corporation
Pozen, Inc.
Q Therapeutics, Inc.
ReCyte Therapeutics, Inc.
Regado Biosciences, Inc.
RegeneRx Biopharmaceuticals, Inc.
Saneron CCEL Therapeutics, Inc.
StemCells, Inc.
SynZyme Technologies, LLC
Targazyme, Inc.
Vicore Pharma AB
Virogenomics, Inc.
WhanIn Pharmaceutical Co., Ltd.
Xigen SA
Acute Ischemic Stroke - Pipeline Review, H2 2014 US$ 1,800.00 Aug, 2014 · 102 pages
Acute Ischemic Stroke - Pipeline Review, Q1 2011 US$ 450.00 Feb, 2011 · 61 pages
Stroke - Pipeline Review, Q3 2011 US$ 450.00 Jul, 2011 · 193 pages
FASgen, Inc. – Product Pipeline Review – 2012 US$ 1,350.00 Nov, 2012 · 27 pages

Ask Your Question

Stroke - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: